Menu
Recruiting NCT07596823

Hematological Indices and Sympathetic Block Response in Neuropathic Pain

— Observational Neuropathic Pain Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Neuropathic Pain, Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Hematological Inflammatory Indices as Predictors of Treatment Response to Sympathetic Nerve Blocks in Neuropathic Pain: A Prospective Observational Study

Overview

This prospective observational study aims to evaluate the relationship between hematological inflammatory indices and clinical treatment response in patients with neuropathic pain undergoing sympathetic nerve block procedures as part of routine clinical care. Hematological parameters including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), aggregate index of systemic inflammation (AISI), and red cell distribution width (RDW) will be evaluated before and after treatment. The association between changes in these indices and pain outcomes will be analyzed.

Detailed description

Neuropathic pain is a complex chronic pain condition involving inflammatory, neural, and immune-mediated mechanisms. Increasing evidence suggests that systemic inflammatory processes may contribute to the pathophysiology and persistence of neuropathic pain. Hematological inflammatory indices derived from routine complete blood count parameters have recently emerged as inexpensive and accessible biomarkers reflecting systemic inflammatory status.

Although several studies have investigated inflammatory markers in chronic pain syndromes, data regarding the relationship between hematological inflammatory indices and treatment response following sympathetic nerve block interventions in neuropathic pain are limited.

This prospective observational study aims to evaluate whether hematological inflammatory indices are associated with treatment outcomes in neuropathic pain patients treated with sympathetic nerve block procedures as part of routine clinical management. Adult patients diagnosed with neuropathic pain and scheduled for sympathetic nerve block treatment will be prospectively followed for 3 months.

Clinical outcomes including Numeric Rating Scale (NRS), DN4 and/or LANSS neuropathic pain scores, Global Perceived Effect (GPE), and analgesic consumption will be recorded. Hematological indices including NLR, PLR, MLR, SII, SIRI, AISI, and RDW will be calculated using routine hemogram parameters.

The study is designed as a non-interventional, single-center, prospective observational clinical study. The treatment approach will not be altered for research purposes.

Primary outcome measures

  • Treatment Response at Month 3 [Time frame: 3 th month]
Secondary outcome measures (3)
  • NRS (Numeric Rating Scale Pain Score) [Time frame: Baseline and 3rd month]
  • Change in Hematological Inflammatory Indices [Time frame: Baseline and 3rd monnth]
  • GPE (Global Perceived Effect) [Time frame: 3rd month]

Eligibility criteria

Inclusion criteria

  • Age ≥18 years
  • Diagnosis of neuropathic pain based on clinical evaluation
  • DN4 and/or LANSS scores compatible with neuropathic pain
  • Undergoing sympathetic nerve block as part of routine clinical treatment
  • Availability of pre-treatment and follow-up hemogram parameters
  • Ability to provide written informed consent

Exclusion criteria

  • Age <18 years
  • Active infection or acute inflammatory disease
  • Active malignancy
  • History of hematological disease
  • Immunosuppressive therapy or systemic corticosteroid use
  • Major surgery or severe trauma within the last month
  • Pregnancy or breastfeeding
  • Autoimmune or rheumatologic inflammatory disease
  • Missing follow-up data

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Turkey (Türkiye) · 1 center
  • Ankara Bilkent City Hospital — Ankara

Publications

  • Babaoglu G, Sabuncu U, Dadali S, Costu A, Akcaboy EY. Discriminative role of inflammatory indices in clinical response to ganglion impar blockade: A retrospective cohort study. Medicine (Baltimore). 2026 Feb 6;105(6):e47638. doi: 10.1097/MD.0000000000047638. PMID 41650048

Identifiers

NCT: NCT07596823 · 13579

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗